BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.69) by 16.31 percent. This is a 83.75 percent increase over losses of $(3.57) per share from the same period last year. The company reported quarterly sales of $256.000 thousand which beat the analyst consensus estimate of $250.000 thousand by 2.40 percent. This is a 30.05 percent decrease over sales of $366.000 thousand the same period last year.